# Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)

> **NCT03116971** · PHASE1 · TERMINATED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 2 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** M3814
- **DRUG:** Cisplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT03116971
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-25
- **Primary completion:** 2018-03-01
- **Final completion:** 2018-03-01
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Enrollment in the study was prematurely terminated due to recruitment challenges and not due to concerns of safety for the participants.
- **Last updated:** 2020-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03116971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03116971, "Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03116971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*